Skip to content

Specific and non-specific effects of an H1-antagonist on cognitive information processing

Specific and non-specific effects of an H1-antagonist on cognitive information processing - Specificity of the effects of H1-antagonist

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON29987
Enrollment
18
Registered
2006-11-07
Start date
2006-12-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gezonde vrijwilligers nvt

Interventions

On each testday volunteers recieve either of the following treatments: dexchlorpheniramine 4 mg, lorazepam 1 mg or placebo.

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Males and females Age 18-45 Good physical health as determined by a medical history questionnaire, medical screening by a physician, ECG and blood haematology Absence of any medical, endocrine and neurological condition Body mass index (weight/length2) between 18 and 28 kg/m2 Blood pressure between 100-150 Hg systolic and 60-90 Hg diastolic Written informed consent

Exclusion criteria

Exclusion criteria: History of or current drug abuse Current use of psychoactive medicinal treatment Drinking more than 20 alcoholic consumptions per week For females: pregnancy or lactation Drinking more than 5 cups of caffeinated drinks per day Smoking more than 5 cigarettes per day

Design outcomes

Primary

MeasureTime frame
Reaction time in milliseconds as measured by the choice reaction time task, n-back memory task and word recognition task. The number of memorized words during the immediate recall phase and during the delayed recall (few minutes) phase (45 minutes). Number of correct detected letters in the n-back task. Average deviation from midline as measured by the sub-critical tracking task. The different ERP components: N100/P100, N200/P200, P300, CNV and LRP.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)